Answers are grounded in this paper and cite their sources.
Case report demonstrates that myeloid growth factors exacerbated hemophagocytosis in a myelodysplasia patient, suggesting these therapies may be detrimental.
We describe a 75-year-old man with neutropenia in whom bone marrow aspirate and biopsy demonstrated hemophagocytosis associated with myelodysplasia (MDS). Therapy with granulocyte-colony stimulating factor (G-CSF) and granulocyte-monocyte-colony stimulating factor (GM-CSF) caused splenomegaly and severe thrombocytopenia, which recurred upon rechallenge. We propose that myeloid growth factors may be detrimental in patients with MDS-associated hemophagocytosis.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: